Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER vs PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.
Replacement of extracellular fluid and electrolytes; provides buffering capacity via bicarbonate precursor (acetate) and maintains physiological p H.
Peritoneal dialysis for patients with end-stage renal disease,Correction of fluid and electrolyte imbalances,Correction of metabolic acidosis
Intravenous replacement of intravascular volume and electrolytes in patients with normal or slightly acidic p H,Maintenance of fluid and electrolyte balance during surgery or in critical care,Correction of hypovolemia when isotonic fluid administration is appropriate
Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.
Intravenous infusion, rate adjusted based on clinical status and electrolyte needs; typical adult dose is 500-1000 m L over 1-2 hours.
Terminal elimination half-life is approximately 0.5–1 hour in patients with normal renal function. In end-stage renal disease (ESRD), half-life extends to 6–8 hours, requiring dose adjustment.
Not applicable; components follow first-order kinetics with rapid redistribution. Lactate half-life ~15-30 minutes (hepatic metabolism).
Bicarbonate and lactate are metabolized in the liver and kidneys. Lactate is converted to bicarbonate via hepatic gluconeogenesis and the Cori cycle.
Acetate is metabolized primarily in the liver and muscles to bicarbonate.
Renal: 100% (proximal tubular secretion and glomerular filtration). Biliary/fecal: negligible (<1%).
Primarily renal; >95% of infused ions (sodium, chloride, lactate, calcium, magnesium) are excreted unchanged in urine. Biliary/fecal elimination negligible (<1%).
Approximately 10–20% bound to albumin. Binding is low and clinically insignificant.
Negligible (<1%); ions are free in plasma (no significant protein binding).
Volume of distribution is 0.2–0.3 L/kg (10–20 L in adults), approximating extracellular fluid volume. This small Vd is consistent with limited tissue penetration.
0.4 L/kg; distributes mainly in extracellular fluid (ECF).
Intravenous: 100% (only route of administration).
100% (intravenous); not absorbed orally.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²) due to risk of hyperphosphatemia and hyperkalemia. In mild to moderate impairment (e GFR 30-89): reduce dose by 25-50% and monitor serum potassium and phosphate levels.
Contraindicated in oliguric or anuric renal failure; in GFR <30 m L/min, avoid use or monitor electrolytes closely; no specific GFR-based dose adjustment.
No specific dose adjustment recommended for Child-Pugh class A or B. For Child-Pugh class C: use with caution and consider reducing dose by 25% due to potential for altered phosphate metabolism and encephalopathy risk.
No specific Child-Pugh based adjustments; use with caution in hepatic impairment due to risk of fluid overload.
Dose based on body weight: 1-2 mmol/kg/day of potassium phosphate intravenously as part of parenteral nutrition, with infusion rate not exceeding 0.5 mmol/kg/hour. Maximum daily dose: 4 mmol/kg.
Weight-based dosing: 5-10 m L/kg intravenous infusion over 1-2 hours, not to exceed 30 m L/kg/day.
Start at lower end of dosage range (e.g., 20-30 mmol/day) due to age-related renal function decline. Monitor renal function and serum electrolytes closely; adjust dose based on creatinine clearance.
Use with caution due to increased risk of fluid overload and electrolyte imbalance; adjust rate and volume based on renal function and comorbidities, typical initial dose 500 m L over 2-3 hours.
None.
None.
Peritonitis risk,Catheter-related infections,Fluid and electrolyte disturbances,Metabolic alkalosis (with high bicarbonate levels),Hypokalemia or hyperkalemia,Peritoneal membrane failure
Use with caution in patients with severe renal impairment, heart failure, or conditions associated with sodium retention,Monitor serum electrolytes, fluid balance, and acid-base status during prolonged administration,Risk of volume overload in patients with compromised cardiac or renal function,Contains aluminum; may be toxic with prolonged use in patients with renal impairment
Hypersensitivity to any component,Pre-existing severe metabolic alkalosis,Documented peritoneal membrane failure,Abdominal or peritoneal defects (e.g., hernias, fistulas),Uncorrected mechanical defects in peritoneal cavity
Hypersensitivity to any component,Severe hypernatremia or severe hyperchloremia,Severe metabolic alkalosis,Patients with contraindications to intravenous fluid administration
No direct food interactions, but dietary intake of potassium, calcium, and phosphorus must be managed per clinical guidelines during CRRT. Avoid high-potassium foods (e.g., bananas, oranges, potatoes) unless potassium supplementation is adjusted accordingly.
No food interactions are relevant as Physiosol p H 7.4 is not ingested. It is used exclusively for topical irrigation during medical procedures.
No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or electrolyte imbalances may pose risks. First trimester: theoretical risk of teratogenicity only with severe maternal hyperphosphatemia. Second/third trimesters: risks include fetal hyperphosphatemia, hypocalcemia, and potential soft tissue calcification. Use only if clearly needed.
Physiosol p H 7.4 (balanced electrolyte solution) is considered low risk for teratogenicity. There are no known fetal risks associated with its use in any trimester, as it is a physiological solution. However, large volumes or rapid administration could theoretically cause maternal electrolyte imbalances, which may indirectly affect the fetus.
Potassium phosphate is present in human milk at levels consistent with physiological requirements. Milk-to-plasma ratio not established. Exogenous phosphate is rapidly absorbed and may cause hyperphosphatemia in the infant at high maternal doses. Caution advised; monitor infant for signs of hyperphosphatemia (e.g., hypocalcemia, tetany).
Physiosol p H 7.4 is compatible with breastfeeding. No M/P ratio is available; however, components are normal plasma constituents and unlikely to be excreted into breast milk in clinically significant amounts.
Physiologic increase in plasma volume and glomerular filtration rate in pregnancy may increase phosphate clearance, potentially requiring higher doses to maintain therapeutic levels. However, individualize dosing based on serum phosphate monitoring. No standard dose modification; adjust per clinical response and lab values.
No specific dose adjustment is required for pregnancy. However, consider increased plasma volume and glomerular filtration rate in pregnancy; standard dosing is appropriate, but monitor for volume overload.
PHOXILLUM B22K 4/0 is a bicarbonate-buffered, low-calcium dialysate for continuous renal replacement therapy (CRRT). Monitor serum potassium closely as it contains 4 m Eq/L K+, 0 m Eq/L Ca2+, and 22 m Eq/L bicarbonate. Use with caution in hyperkalemic patients; may require adjustment of potassium supplementation. Ensure adequate calcium replacement via separate infusion to avoid hypocalcemia. Verify compatibility with other IV fluids and medications administered through the CRRT circuit.
Physiosol p H 7.4 is a balanced crystalloid solution used for irrigation, not for systemic administration. In the operating room, it is preferred for peritoneal lavage due to its neutral p H, which minimizes tissue irritation. Do not use for intravenous infusion; verify labeling to avoid confusion with IV solutions. Warm to body temperature before use to prevent hypothermia during large-volume irrigation.
This solution is used only during continuous dialysis in the hospital setting; it is not for direct infusion into your vein.,Your healthcare team will monitor your blood potassium and calcium levels closely while you receive this treatment.,Do not eat or drink anything unless your doctor or nurse approves, as your diet may need to be adjusted.,Report any muscle cramps, tingling, or irregular heartbeat to your nurse immediately.
This solution is used to rinse body cavities during surgery, not for intravenous use.,You may feel a cooling sensation during irrigation; this is normal.,Report any signs of infection at the surgical site, such as redness, swelling, or discharge.,Do not attempt to use this solution at home; it is for hospital use only.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER vs PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER, answered by our medical review team.
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is a Irrigation Solution that works by PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.. PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER is a Irrigation Solution that works by Replacement of extracellular fluid and electrolytes; provides buffering capacity via bicarbonate precursor (acetate) and maintains physiological p H.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER and PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Irrigation Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is: Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.. The standard adult dose of PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER is: Intravenous infusion, rate adjusted based on clinical status and electrolyte needs; typical adult dose is 500-1000 m L over 1-2 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER and PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is classified as Category C. No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or elect. PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER is classified as Category C. Physiosol pH 7.4 (balanced electrolyte solution) is considered low risk for teratogenicity. There are no known fetal risks associated with its use in any trimester, as it is a phys. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.